3rd Conference on Active Surveillance for Low Risk Prostate Cancer

Chairs: C.H. Bangma, NL - J. Hugosson, SE
Co Chair: L.H. Klotz, CAN
Honorary Chair: L.J. Denis, BE
Host Chair: R. Valdagni, IT
Scientific Coordinators: P.R. Carroll, US - M.J. Roobol, NL

 

CONFERENCE OVERVIEW
Active surveillance is increasingly becoming an accepted initial strategy for the treatment of low risk prostate cancer.
Unless the over-diagnosis of prostate cancers is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role.
The challenge is to determine how and if new imaging technologies and genomic biomarkers can improve patient selection and monitoring. In addition, there is the challenge on how to incorporate the choice of available drugs into active surveillance programmes.

ESO’s third Inside Track Conference “Active surveillance for Low Risk Prostate Cancer” is organized in collaboration with EAU and endorsed by Europa Uomo. It aims at being an interactive educational activity in which attendees will enjoy presentations by internationally renowned researchers on active surveillance, who have helped develop and evaluate technologies that may change the selection and monitoring of low risk prostate cancer patients.

Furthermore, participatory workshops will allow discussions on a few selected hot topics with top experts in that field. Remarks and conclusions of the workshops will give important insights into active surveillance practices applied in various countries.
 
This multidisciplinary and multi-professional conference will provide highlights on the different aspects of a personalised approach to prostate cancer management in general and, in particular, on:

• Who to select for active surveillance and what can be the role of MRI and genetic markers
• Optimization of follow up protocols reducing unnecessary biopsies and when to switch to watchful waiting
• Quality of life and patient perspectives


TARGET AUDIENCE
The Conference is targeted towards urologists, radiation oncologists, medical physicists, medical oncologists, pathologists, biostatisticians and investigators in outcomes research and genomics.


LEARNING OBJECTIVES
As a result of attending this activity, participants will be expected:

• Update on the state-of-the-art of active surveillance for low risk prostate cancer patient
• Understand the future research trends within the oncologic community


MAIN TOPICS
• Who to select for active surveillance and what can be the role of MRI and genetic markers
• Optimization of follow up protocols reducing unnecessary biopsies and when to switch to watchful waiting
• Quality of life and patient perspectives

 

Endorsed by							In collaboration with

ORGANISING SECRETARIAT
Rita De Martini
Prostate Cancer Programme
European School of Oncology
20121 Milan (Italy)

Programme and organisation:
Rita De Martini (prostate@eso.net) - Tel:+39 02 85464527 - Fax: +39 02 85464545

Registrations and abstracts:
Elena Fiore (efiore@eso.net) - Tel. + 39 02 85464529 - Fax: +39 02 85464545


VENUE
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian 1 - 20133 Milan, Italy
www.istitutotumori.mi.it


CME ACCREDITATION
Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 12 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

CREDITI CCC SIUrO (Società Italiana di Urologia Oncologica)
			Questo evento fa parte del percorso formativo SIUrO "Core Curriculum Uro-Oncologico Certificate" e dà diritto a 12 crediti CCC. Per maggiori informazioni consultare il sito www.siuro.it.

EAU ACCREDITATION
The granted credits will be recognised by EBU (European Board of Urology) accreditation system. Participants of the EU-ACME programme (members of the international urological societies as European Association of Urology, European Society of Paediatric Urology and International Continence Society as well as national urological societies from: Austria, Czech Republic, Cyprus, Denmark, Egypt, Estonia, Greece, Hungary, Italy, The Netherlands, Poland, Portugal, Romania, Serbia, Turkey) may inform ESO on their interest in having the credits recognised by EBU. On their notification, ESO will provide EU-ACME office with the member’s details for the registration in the accreditation system.


OFFICIAL LANGUAGE
The official language of the Conference is English: No simultaneous translation will be provided.


BADGE
The name badge is the only official evidence of registration and should be worn at all times during the Conference.


INSURANCE
The organisers bear no responsibility for untoward events in relation with the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.


FILMING, AUDIO-TAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.


REGISTRATION DESK, OPENING HOURS
Friday, 12 February (7:30-17:30)
Saturday, 13 February (8:00-17:15)


SPONSOR LECTURE
Friday, 12 February 2016 (17:30-18:00)
Sponsored lecture
Genomic Health
Defining clinical utility for genomic tests in Gleason 3+3/3+4 patients
Chair: P.R. Carroll, US


SPONSORS
ESO wishes to extend its appreciation to the sponsors for having granted their participation and support to the conference:

FACULTY
C. Bangma, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
L. Bellardita, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Bokhorst, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
A. Briganti, Urological Research Institute, Ospedale San Raffaele, Milan, IT
S.M. Bruinsma, Dept. of Public Health, Erasmus University Medical Center, Rotterdam, NL
S. Carlsson, Dept of Surgery and Dept of Urology, Memorial Sloan-Kettering Cancer Center, New York, US and Sahlgrenska Academy at the University of Gothenburg, SE
P.R. Carroll, Dept. of Urology, UCSF - Helen Diller Family, Comprehensive Cancer Center, University of California, San Francisco, US
L.J. Denis, Europa Uomo, Oncology Centre Antwerp, BE
J. Humblet, Europa Uomo, Mechelen, BE
J. Hugosson, Dept of Urology, Sahlgrenska Academy at the University of Gothenburg, SE
G. Jenster, Dept of Urology, Erasmus University Medical Center, Rotterdam, NL
L.H. Klotz, Division of Urology, Sunnybrook Health Sciences Centre, Toronto, CA
I. Korfage, Dept. of Public Health, Erasmus University Medical Center, University Medical Centre, Rotterdam, NL
A. Lane, School of Social and Community Medicine, University of Bristol, Bristol, UK
C. Moore, Dept. of Surgical and Interventional Science, University College, London, UK
A. Ouzzane, Service d’Urologie, Hopital Huriez, Centre Hospitalier Regional Universitaire, Lille, FR
T. Pickles, Dept. of Radiotherapy and Developmental Radiotherapeutics Radiation Oncology, BC Cancer Agency, Vancouver, CA
A. Ranniko, Dept of Urology, Helsinki University Hospital, Helsinki, FI
M.J. Roobol, Dept. of Urology/Epidemiology, Erasmus University Medical Center, Rotterdam, NL
I. Schoots, Dept. of Radiology, Erasmus University Medical Center, Rotterdam, NL
A. Semjonow, Dept. of Urology, University Hospital Munster, Munster, DE
E. Steyerberg, Dept. of Public Health, Erasmus University Medical Center, Rotterdam, NL
K. Touijer, Dept. of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, US
B.J. Trock, Department of Urology, Johns Hopkins School of Medicine, Baltimore, US
R. Valdagni, Prostate Cancer Programme and Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
H. Van Poppel, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, BE
L. Venderbos, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
J. Walz, Dept. of Urology, Institut Paoli-Calmettes, Marseille, FR

 FEBRUARY 12

7:30		Registration
9:00		Welcome and introduction
		Welcome R. Valdagni, IT
		Introduction C. Bangma, NL
9:15		Overview of active surveillance in ERSPC J. Hugosson, SE
SESSION 1 - SETTING THE STAGE: DO WE NEED ACTIVE SURVEILLANCE IN THE FUTURE? Chairs: J. Hugosson, SE - A. Semjonow, DE
9:30		Can we reduce over-diagnosis? M.J. Roobol, NL
9:50		Ethical and legal considerations L. Venderbos, NL
10:10		An update on the Movember GAP-3 project S.M. Bruinsma, NL
10:30		Discussion
10:40		Coffee break
SESSION 2 - CURRENT SELECTION OF MEN FOR ACTIVE SURVEILLANCE Chairs: C. Bangma, NL - A. Briganti, IT
11:00		Traditional selection of men for active surveillance K. Touijer, US
11:20		Broadening inclusion criteria (Gleason 3+4/ extended Gleason 3+3) L.H. Klotz, CA
11:40		Risk-based selection for active surveillance E. Steyerberg, NL
12:05		Value of MRI and targeted biopsies P.R. Carroll, US
12:25		Better informed decision making to select more men for active surveillance L. Bellardita, IT
12:45		Structured panel discussion with input from audience Panelists: L. Bellardita, IT - P.R. Carroll, US - L.H. Klotz, CA - E. Steyerberg, NL - K. Touijer, US
13:15		Lunch and poster viewing
BEST POSTERS SESSION Chair: P.R. Carroll, US
14:10		Follow-up of men on Active Surveillance for low-grade prostate cancer with multiparametric MRI and targeted biopsy instead of TRUS-guided systematic biopsy could safely reduce the number of biopsy procedures A. Arnout, NL
14:20		Younger age is associated with decreased risk of biopsy progression during active surveillance for low and intermediate risk prostate cancer J. Cowan, US
14:30		Active Surveillance in Intermediate-Risk Patients: Survival Outcomes in the Sunnybrook Experience L. Klotz, CA
EAU LECTURE Chairs: H. Van Poppel, BE - B.J. Trock, US
14:45		Imaging and active surveillance J. Walz, FR
SESSION 3 - EVALUATION OF NEW PARAMETERS Chairs: C. Moore, UK - B.J. Trock, US
15:15		Value of genetic profiles in active surveillance S. Carlsson, US
15:30		Value of serum markers in active surveillance B.J. Trock, US
15:45		The power of genetic profiling for low risk prostate cancer G. Jenster, NL
16:00		Discussion
16:15		MRI to target biopsies A. Ouzzane, FR
16:30		Objective parameters in MRI? I. Schoots, NL
16:45		Can MRI replace biopsies during follow-up? C. Moore, UK
17:00		Discussion
17:30		Sponsored lecture 1

 

 FEBRUARY 13

8:00		Registration
SESSION 4 - MONITORING OF MEN ON ACTIVE SURVEILLANCE Chairs: T. Pickles, CA - R. Valdagni, IT
9:00		Number and frequency of follow-up tests L. Bokhorst, NL
9:20		Triggers for reclassification A. Rannikko, FI
9:40		When to stop active surveillance / switch to watchful waiting A. Semjonow, DE
10:00		Active monitoring in the ProtecT study A. Lane, UK
10:20		Highlights of the MRI Session C. Moore, UK
10:30		Structured panel discussion with input from audience Panelists: L. Bokhorst, NL - A. Lane, UK - C. Moore, UK - A. Rannikko, FI - A. Semjonow, DE
11:00		Coffee break
SESSION 5 - QUALITY OF LIFE OF MEN ON ACTIVE SURVEILLANCE Chairs: L. Bellardita, IT - P.R. Carroll, US
11:30		Can we better select men for active surveillance when adding psychological assessment? A. Lane, UK
11:50		Comparison of long term quality of life between active surveillance and active treatment I. Korfage, NL
12:10		Patient’s perspective J. Humblet, BE
12:30		Discussion
12:45		Lunch
SESSION 6 - SIMULTANEOUS WORKSHOPS (13:45 - 15:00)
		Workshop #1 - Which biomarkers/imaging/clinical characteristics should we use to select men with Gleason 3+4 for active surveillance? (M.J. Roobol, NL - S. Carlsson, US)
		Workshop #2 -Which quality of life measures should we routinely use in men on active surveillance? Which questions should still be answered? (L. Bellardita, IT - L. Venderbos, NL)
		Workshop #3 - What kind of interventions (food/ lifestyle/ medical) should we study in men on active surveillance? How to study them? (L.H. Klotz, CA - T. Pickles, CA)
		Workshop #4 -What should the definition of progression on MRI in men on active surveillance be? How to study it? (C. Moore, UK - I. Schoots, NL)
15:00		Coffee break
SESSION 7 - REPORTS OF THE WORKSHOPS (15:15 - 16:15) Chairs: P.R. Carroll, US and Co-Chair to be announced
		• Workshop #1
		• Workshop #2
		• Workshop #3
		• Workshop #4
HOT DISCUSSION Chairs: C. Bangma, NL - J. Hugosson, SE
16:30		Is selective identification of low risk prostate cancer currently possible or will it become possible in the near future? Panelists: P.R. Carroll, CA - J. Hugosson, SE - L.H. Klotz, CA -M.J. Roobol, NL - K. Touijer, US - B.J. Trock, US - R. Valdagni, IT - H. Van Poppel, BE
17:00 17:10		Closing remarks R. Valdagni, IT

 POSTER SESSION

		Poster Session Abstracts received by participants have been considered and selected by poster presentation only, except for the three best abstract posters that will be presented both as posters and as a 10 minute oral presentation on Friday 12 February at 14:10. Accepted abstracts have been published in the event’s dedicated website.
1		Active surveillance for low-risk prostate cancer: 1-year experience of a single center prospective study. Mihhail Žarkovski, EE
3		Active Surveillance in Spain; Multicentric database from the Spanish Urological Association. Characteristics of a new multicentric register on active surveillance in prostate cancer. Jose Rubio Briones, ES
7		How do men with localized prostate cancer estimate their mortality risk? Friederike Kendel, DE
10		Preliminary results from AEU/PIEM/2014/0001, the Spanish Association of Urology  (AEU) Register on Active Surveillance in prostate cancer. Angel Borque Fernando, ES
16		Serial Anatomic Prostate Ultrasound Imaging During Prostate Cancer Active Surveillance. Janet Cowan, US
17		Development and usability testing of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) Smartphone Application for iOS. Nuno Pereira Azevedo, PT
18		Follow-up of men on Active Surveillance for low-grade prostate cancer with multiparametric MRI and targeted biopsy instead of TRUS-guided systematic biopsy could safely reduce the number of biopsy procedures. Alberts Arnout, NL
19		Younger age is associated with decreased risk of biopsy progression during active surveillance for low and intermediate risk prostate cancer. Janet Cowan, US
20		Fusion MRI-Ultrasound Biopsy during Prostate Cancer Active Surveillance. Janet Cowan, US
21		Results of serial testing of a 17-gene genomic prostate score in prostate cancer patients on active surveillance. Janet Cowan, US
22		Clinical risk stratification in active surveillance patients for safely passing their second repeat biopsy in the PRIAS protocol. Frank-Jan Drost, NL
23		External Validation of a Prognostic Gleason Grade Classification System. Janet Cowan, US
25		Active Surveillance in Intermediate-Risk Patients: Survival Outcomes in the Sunnybrook Experience. Laurence Klotz, CA
26		Facing untreated prostate cancer on active surveillance: who is at risk for increased anxiety? Silvia Villa, IT
27		Prostate cancer patients on active surveillance: is physical activity associated with health-related quality of life? Julia Paola Menichetti Delor, IT
28		Concordance of pathologic reports in the reviews of the biopsies of prostate cancer patients (pts) included in active surveillance (AS) at Milan National Cancer Institute. Maurizio Colecchia, IT
29		Cost-Effectiveness of Active Surveillance compared to Immediate Treatment: A modelling study. Tiago De Carvalho, NL
30		Biopsy driven complications as scored by a self-reported questionnaire: preliminary results. Maria Francesca Alvisi, IT
31		No prostate cancer found during Active Surveillance re-biopsies: analysis of a single institution population. Fabio Badenchini, IT
32		Early reclassification vs long Active Surveillance: results from a single institution population. Maria Francesca Alvisi, IT
33		SIUrO-PRIAS-ITA, six years experience in Active Surveillance. Fabio Badenchini, IT
34		A validation analysis confirming different predictors of upgrading and upsizing at 1-year repeat biopsy in low-risk prostate cancer patients on active surveillance. Nicola Nicolai, IT
35		START (Active Surveillance or Radical Treatment for newly diagnosed patients with a localized, low risk, prostate cancer): a new management and organizational model in the Oncology Network of Piedmont and Valle d’Aosta (Northern Italy). Claudia Galassi, IT

 

ABSTRACT SUBMISSION

The abstract deadline is passed (17 December 2015)

Participants were invited to submit abstract on research relating to the identification of potential indolent prostate cancer or on clinical studies relating to active surveillance of prostate cancer.

Abstracts will be considered for poster presentations only. The three best abstracts will be selected and presented both as posters and as a 10-minute oral presentation on Friday, 12 February 2016. The three best abstracts will furthermore be awarded a prize of € 200 each.

Ample opportunity will be given to the conference participants to view all posters. The Chair of the Poster Session will visit all posters and participants will be able to give a short oral explanation of the research described (no slides).
The Poster Session is scheduled on Friday, 12 February (13:15-14:15).

Accepted abstracts will be published in the event’s dedicated website.

Instructions:

•		The number of words is limited: 50 words for the title (lower case letter) and 450 words (maximum 2800 characters) for the body of the abstract. The abstracts should be limited to 2000 characters, including the title.
•		Tables and images are not accepted.
•		Each author should be listed with First name, followed by Family Name.
•		The first author will be the corresponding author and the presenter at the Conference.
•		List the authors’ affiliations. The same affiliation should be entered only once.
•		The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent communication by e-mail.
•		For abstracts accepted for poster presentation and best abstract oral presentation, the first author will be the presenting author and is requested to register and participate in the Conference.
•		It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of abstract will immediately follow the submission.
The outcome will be notified by 21 December 2015 to the first author who will be required to register to the Conference (early registration deadline: 21 December 2015).

.